urokinase inhibitor 1

MK-1064 (Urokinase inhibitor 1) is a selective orexin 2 receptor antagonist (2-SORA).

4-Aminobenzamidine dihydrochloride (p-Aminobenzamidine dihydrochloride) is a strong trypsin inhibitor and a relatively weak inhibitor of urokinase type plasminogen activator (uPA) (K i =82 μM). 4-Aminobenzamidine can inhibit growth of a human prostate tumor in SCID mice [1] [2].

UKI-1 is a urokinase-type plasminogen activator system synthetic inhibitor.

ZK824190 is an orally available and selective inhibitor of urokinase plasminogen activator (uPA), with IC50 values of 237 nM for uPA, 1600 nM for tPA, and 1850 nM for Plasmin.

CDE-096 is a potent inhibitor of plasminogen activator inhibitor-1 that prevents PAI-1–mediated inactivation of tissue plasminogen activator and urokinase plasminogen activator with nanomolar potency, while maintaining activity against glycosylated and multispecies PAI-1, enabling translational research in fibrinolysis and thrombosis regulation.

GGACK is an inhibitor of urokinase-type plasminogen activator (uPA) and factor Xa (Kis = 1.8 and 8.7 μM, respectively).1,2 1.Kettner, C., and Shaw, E.The susceptibility of urokinase to affinity labeling by peptides of arginine chloromethyl ketoneBiochim. Biophys. Acta569(1)31-40(1979) 2.Kettner, C., and Shaw, E.The selective affinity labeling of factor Xa by peptides of arginine chloromethyl ketoneThromb. Res.22(5-6)645-652(1981)

Vitronectin, a multifunctional glycoprotein found in blood and the extracellular matrix, interacts with glycosaminoglycans, collagen, plasminogen, and the urokinase-receptor, in addition to stabilizing the inhibitory conformation of plasminogen activation inhibitor-1. It is utilized in research related to wound healing and tumor progression [1].

Anti-SERPINE1 Antibody is a humanized monoclonal antibody targeting Serpin Family E Member 1 (SERPINE1/PAI-1). SERPINE1, also known as Plasminogen Activator Inhibitor-1 (PAI-1), is the primary physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, playing a critical role in regulating fibrinolysis, cell migration, and tissue remodeling. Elevated PAI-1 levels are associated with thrombosis, fibrosis, metabolic syndrome, and tumor progression (including immune evasion and metastasis). Anti-SERPINE1 Antibody specifically binds to PAI-1, neutralizing its inhibitory activity and restoring tPA/uPA-mediated plasmin generation to promote fibrinolysis and reduce extracellular matrix deposition. Additionally, the antibody blocks PAI-1-mediated upregulation of PD-L1, thereby enhancing anti-tumor immune responses in the tumor microenvironment, and possesses potential anti-senescence properties.

PAI-1 is a plasminogen activator inhibitor. It belongs to the serine protease (Ser Protease) inhibitor superfamily and exhibits antiprotease activity. PAI-1 is the primary physiological inhibitor of tissue-type (tPA) and urokinase-type (uPA) plasminogen activators (PAs).